Lenvatinib，又称乐伐替尼，是一种可口服的多靶点酪氨酸激酶(RTK)抑制剂，作用于VEGFR1/2/3和PDGFRα/β的IC₅₀值分别为22/4/5.2 nM、51/39 nM，临床上用于治疗甲状腺癌。

参考文献

[1] Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008 Feb 1;122(3):664-71. doi: 10.1002/ijc.23131(IF:4.982).

[2] Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008 Sep 1;14(17):5459-65. doi: 10.1158/1078-0432(IF:8.911).

-25~-15℃保存，有效期3年。